CN120289456A - Enl/af9 yeats抑制剂 - Google Patents

Enl/af9 yeats抑制剂 Download PDF

Info

Publication number
CN120289456A
CN120289456A CN202510375451.1A CN202510375451A CN120289456A CN 120289456 A CN120289456 A CN 120289456A CN 202510375451 A CN202510375451 A CN 202510375451A CN 120289456 A CN120289456 A CN 120289456A
Authority
CN
China
Prior art keywords
methyl
alkyl
compound
resulting solution
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510375451.1A
Other languages
English (en)
Chinese (zh)
Inventor
坦维尔·A·卡恩
奈杰尔·利弗顿
深濑喜之
道野摩耶子
安德鲁·W·斯坦福
迈克尔·W·米勒
大卫·哈金斯
彼得·米克
大卫·C·艾利斯
万李玲
约瑟夫·维卡
塔米·拉杜瓦赫蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bridge Pharmaceutical Co ltd
Rockefeller University
Original Assignee
Bridge Pharmaceutical Co ltd
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridge Pharmaceutical Co ltd, Rockefeller University filed Critical Bridge Pharmaceutical Co ltd
Publication of CN120289456A publication Critical patent/CN120289456A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202510375451.1A 2019-12-17 2020-12-17 Enl/af9 yeats抑制剂 Pending CN120289456A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962949160P 2019-12-17 2019-12-17
US62/949,160 2019-12-17
PCT/US2020/065593 WO2021127166A1 (en) 2019-12-17 2020-12-17 Inhibitors of enl/af9 yeats
CN202080096854.8A CN115427035B (zh) 2019-12-17 2020-12-17 Enl/af9 yeats抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080096854.8A Division CN115427035B (zh) 2019-12-17 2020-12-17 Enl/af9 yeats抑制剂

Publications (1)

Publication Number Publication Date
CN120289456A true CN120289456A (zh) 2025-07-11

Family

ID=76476792

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510375451.1A Pending CN120289456A (zh) 2019-12-17 2020-12-17 Enl/af9 yeats抑制剂
CN202080096854.8A Active CN115427035B (zh) 2019-12-17 2020-12-17 Enl/af9 yeats抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080096854.8A Active CN115427035B (zh) 2019-12-17 2020-12-17 Enl/af9 yeats抑制剂

Country Status (14)

Country Link
US (1) US20230027198A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076440B1 (cg-RX-API-DMAC7.html)
JP (1) JP7840851B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220129554A (cg-RX-API-DMAC7.html)
CN (2) CN120289456A (cg-RX-API-DMAC7.html)
AU (1) AU2020407589A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012273A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162253A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022009852A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220326A (cg-RX-API-DMAC7.html)
IL (1) IL293839A (cg-RX-API-DMAC7.html)
MX (1) MX2022007442A (cg-RX-API-DMAC7.html)
PH (1) PH12022551529A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021127166A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518824A (ja) 2021-05-13 2024-05-07 ブリッジ メディシンズ Enl/af9 yeatsのc結合阻害剤
CN117580944A (zh) * 2021-08-03 2024-02-20 苏州沙砾生物科技有限公司 一种修饰的免疫细胞及其用途
US20250376473A1 (en) * 2022-07-01 2025-12-11 Cytosinlab Therapeutics Co., Ltd. Prmts inhibitor and use thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
US20260078121A1 (en) * 2022-09-08 2026-03-19 Bridge Medicines Inhibitors of enl/af9 yeats and flt3
WO2024140923A1 (zh) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Prmt5-mta抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2375359C2 (ru) * 2004-09-03 2009-12-10 Юхан Корпорейшн ПРОИЗВОДНЫЕ ПИРРОЛО[3, 2-c]ПИРИДИНА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US20110015225A1 (en) * 2008-04-01 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2522657B1 (en) * 2010-01-06 2016-08-03 Takeda Pharmaceutical Company Limited Indole derivative
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
WO2022146920A1 (en) * 2020-12-28 2022-07-07 Celgene Corporation Heterocyclic compounds and their use for parasitic diseases
JP2024518824A (ja) * 2021-05-13 2024-05-07 ブリッジ メディシンズ Enl/af9 yeatsのc結合阻害剤

Also Published As

Publication number Publication date
JP2023527487A (ja) 2023-06-29
CA3162253A1 (en) 2021-06-24
JP7840851B2 (ja) 2026-04-06
CN115427035B (zh) 2025-04-22
CO2022009852A2 (es) 2022-10-11
MX2022007442A (es) 2023-02-13
EP4076440A1 (en) 2022-10-26
US20230027198A1 (en) 2023-01-26
EP4076440B1 (en) 2026-07-08
IL293839A (en) 2022-08-01
KR20220129554A (ko) 2022-09-23
CR20220326A (es) 2023-02-10
PH12022551529A1 (en) 2024-02-05
CN115427035A (zh) 2022-12-02
WO2021127166A1 (en) 2021-06-24
AU2020407589A1 (en) 2022-07-21
EP4076440A4 (en) 2023-11-08
BR112022012273A2 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
CN115427035B (zh) Enl/af9 yeats抑制剂
CN112204029B (zh) 治疗性化合物
CN110088099B (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法
CN106817899B (zh) 作为rock抑制剂的螺环庚烷
CN102325752B (zh) 咔唑和咔啉激酶抑制剂
CN108699038B (zh) 作为Rock抑制剂的螺环庚烷水杨酸酰胺和相关化合物
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
CN107873031B (zh) 作为tnf活性调节剂的苯并噁嗪酮衍生物及其类似物
CN105916857B (zh) 吡咯并吡咯酮衍生物及其作为bet抑制剂的用途
CN114981268A (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
CN104470925A (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
CN117858877A (zh) Enl/af9 yeats的c连接抑制剂
KR20220140710A (ko) 트리아졸로피리다진 유도체, 이의 제조 방법, 약물 조성물 및 용도
WO2024067675A1 (zh) 稠环类kif18a抑制剂化合物、药物组合物及其制备方法和应用
CN105073715A (zh) 二氢哒嗪-3,5-二酮衍生物
CN115427044A (zh) 作为补体抑制剂的吡咯并嘧啶胺
WO2024149189A1 (zh) 芳香酰胺类衍生物及其制备方法和用途
CN116546985A (zh) 吡啶并嘧啶类衍生物及其制备方法和用途
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN112300154B (zh) 一类含氮杂环化合物、其制备方法和用途
CN111747954B (zh) 吡嗪化合物和其用途
CN112279837B (zh) 吡嗪化合物和其用途
WO2024175121A1 (zh) α,β-不饱和酰胺类化合物及其应用
TWI893486B (zh) 稠合雙環化合物及其等作為mer及axl抑制劑的用途
CN113754685B (zh) 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination